Last reviewed · How we verify

SIR-Sphere — Competitive Intelligence Brief

SIR-Sphere (SIR-Sphere) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Radioembolization agent. Area: Oncology.

phase 3 Radioembolization agent Yttrium-90 (Y-90) beta emitter Oncology Small molecule Live · refreshed every 30 min

Target snapshot

SIR-Sphere (SIR-Sphere) — Assistance Publique - Hôpitaux de Paris. SIR-Sphere delivers yttrium-90 radiation directly to liver tumors via microspheres injected into the hepatic artery.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
SIR-Sphere TARGET SIR-Sphere Assistance Publique - Hôpitaux de Paris phase 3 Radioembolization agent Yttrium-90 (Y-90) beta emitter

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Radioembolization agent class)

  1. Assistance Publique - Hôpitaux de Paris · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SIR-Sphere — Competitive Intelligence Brief. https://druglandscape.com/ci/sir-sphere. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: